VOZOL Unveils UK Debut of Open-Pod Ace Max with 'Largest HD Touch Screen'

Market by 2FIRSTS.ai
Dec.13.2024
VOZOL Unveils UK Debut of Open-Pod Ace Max with 'Largest HD Touch Screen'
VOZOL introduces new open system e-cigarette, Ace Max, featuring world's largest HD touch screen, now available in UK.

Special announcement:

This article is intended for internal industry communication only and does not make any recommendations for brands or products.

The images presented in this article are used solely to depict factual information and are not intended as advertisements for any products.

This article prohibits access for minors.


Recently, it has come to the attention of 2Firsts that the well-known e-cigarette brand VOZOL has launched a new open system, the VOZOL Ace Max, on its official website. The brand's promotion claims that this product features "the world's largest high-definition touch screen." Currently, the VOZOL Ace Max is available on the websites of e-cigarette distributors in the UK, such as vapesuperstore and ideavape.

 

VOZOL official website showcases its first open system product

 

VOZOL Unveils UK Debut of Open-Pod Ace Max with 'Largest HD Touch Screen'
VOZOL Ace Max | Image Source: VOZOL Official Website

 

Specifically, the product features of VOZOL Ace Max are as follows:

 

VOZOL Unveils UK Debut of Open-Pod Ace Max with 'Largest HD Touch Screen'
VOZOL Ace Max product specifications | Graphic: 2Firsts

 

According to the information posted on the official website of the VOZOL brand, VOZOL Ace Max is the only open system product showcased by the brand. It belongs to the "ACE" product series and its main feature is the 1.47-inch touch screen display, which shows data including power, inhalation count, and battery level.

 

The only e-liquid product displayed on the VOZOL official website

 

On the official website for VOZOL Ace Max, the "Product Recommendations" section displays an e-liquid product available in two nicotine concentrations, 20mg and 50mg, and two sizes, 10ml and 30ml. The brand also offers a variety of 60 different flavors for consumers to choose from.

 

VOZOL Unveils UK Debut of Open-Pod Ace Max with 'Largest HD Touch Screen'
VOZOL E-liquid | Image source: VOZOL official website

 

This e-liquid is currently the only e-liquid product displayed on the official website of the VOZOL brand.

 

It is reported that VOZOL Ace Max was officially launched on the official website of VOZOL in November this year. Currently, the product is available on e-cigarette distributor websites such as vapesuperstore and ideavape in the UK, with a selling price of around £29.99.

 

VOZOL Unveils UK Debut of Open-Pod Ace Max with 'Largest HD Touch Screen'
VOZOL Ace Max real picture | Image source: ideavape

 

2Firsts discovered through online e-cigarette retailers such as vapesourcing, vapeclub, zerovapes, that the VOZOL brand mainly sells disposable e-cigarettes and a few pod systems. As of the time of writing, there have been no other open system products from the VOZOL brand except for the VOZOL Ace Max.

 

2Firsts will continue to monitor the performance and market trends of e-cigarette products globally, providing the public with accurate and authoritative industry information.

 


The product section focuses on providing readers with the latest information in the tobacco industry, welcoming submissions from readers to share the newest products in the e-cigarette field.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Canada Health Minister Says She Is Not Considering Looser Nicotine Pouch Retail Rules as PMI-Linked Group Pushes for Wider Access
Canada Health Minister Says She Is Not Considering Looser Nicotine Pouch Retail Rules as PMI-Linked Group Pushes for Wider Access
Canadian Health Minister Marjorie Michel says she is not considering loosening retail restrictions on nicotine pouches. Canada regulates pouches containing 4 mg or less of nicotine per unit as non-prescription nicotine replacement therapy and requires newer NRT formats such as pouches to be sold from behind pharmacy counters. Meanwhile, Unsmoke Canada, linked to Philip Morris International's Canadian business, is pushing to allow pouches in convenience stores and other general retail outlets. Health Canada also acknowledges continued unauthorized sales, while recent research shows rising pouch use among Canadian youth aged 16 to 19.
Sep.24
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology (NYSE: RLX) has been removed from the FTSE All-World Index, effective September 21. FTSE Russell records show RLX was already part of its global equity index universe by 2022, when its American depositary receipts were classified as China Large Cap securities. Trading volume rose to about 44.77 million shares on September 18, roughly 23 times the previous session's volume. RLX reported RMB1.0105 billion in second-quarter revenue, up 14.8% year over year, with international operations contributing 68.5%. The company also acquired a 51% stake in one of Western Europe's largest distributors of next-generation smoke-free and FMCG products in July.
Sep.22
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
Private antitrust litigation stemming from Altria's 2018 $12.8 billion investment for a 35% economic interest in JUUL is advancing before the U.S. Court of Appeals for the Ninth Circuit. Direct purchasers, indirect purchasers and indirect resellers of JUUL products filed answering briefs this week seeking to preserve class certifications granted by a California federal court in February. Altria and JUUL argue that individual consumers and large distributors differ too much in purchasing terms to remain in a single direct-purchaser class, while a separate dispute concerns whether California antitrust law can apply to indirect purchasers across 27 jurisdictions. A September trial has been put on hold during the appeal.
Sep.23
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08